# Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

> **NCT05046795** · PHASE3 · COMPLETED · sponsor: **Mylan Pharma UK Ltd.** · enrollment: 258 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Revefenacin 175 mcg in 3 ML Inhalation Solution
- **DRUG:** Placebo inhalation solution QD

## Key facts

- **NCT ID:** NCT05046795
- **Lead sponsor:** Mylan Pharma UK Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-10
- **Primary completion:** 2023-07-26
- **Final completion:** 2023-07-26
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05046795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05046795, "Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05046795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*